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Background
Why a needs assessment?
A recent update on access to evidence-based HIV 
interventions outlined the enormous progress made 
towards achieving universal access to antiretroviral therapy 
(ART) over the past decade while revealing significant 
gaps in the response to HIV, particularly in access to health 
sector HIV interventions for paediatric populations.1  
The World Health Organization’s (WHO) Progress 
report 2011: Global HIV/AIDS response revealed that HIV-
infected children continue to suffer high morbidity and 
mortality rates in the first years of life.  It also highlights 
the fact that infants and children have lower access to HIV 
diagnosis, treatment and care services compared with adult 
populations, and face a wide range of co-morbid conditions, 
including tuberculosis (TB), diarrhoeal disease, other 
microbial infections and malnutrition.  While global access 
to the most effective antiretroviral (ARV) prophylaxis to 
prevent vertical transmission increased to 48% in 2010, 
early infant diagnosis coverage at two months was only 
28%.1  Important gaps remain in early identification of 
HIV-exposed infants, linkage to treatment programmes 
and retention in care between the third and fourth prongs 
of prevention of mother to child transmission (PMTCT) 
programmes.* 
Globally, only 23% of children (15 years of age or younger) 
had access to antiretroviral therapy (ART) in low- and 
middle-income countries at the end of 2010 compared 
with 51% of adults.  This underscores the need to improve 
clinical management and evaluate models of integrated care 
that will better serve the needs of paediatric populations. 
The rapid expansion of access to ART in low- and middle-
income countries over the past decade has also resulted in 
a rapidly expanding population of HIV-infected and HIV-
exposed uninfected (HEU) children and adolescents who 
are growing up and reaching sexual maturity.  The need 
to develop evidence-based adherence support and sexual 
and reproductive health interventions tailored to these 
populations will be critical in the global AIDS response in 
the coming years. 
The International AIDS Society (IAS) has worked to 
accelerate the research agenda for women and children 
through the work of its Industry Liaison Forum (IAS-
ILF) and by identifying clinical and operational research 
questions aimed at improving access to more effective 
diagnostic, treatment and care interventions for 
paediatric populations. In March 2010, following a year-
long comprehensive literature review and consultation 
process, the IAS released the consensus statement,  Asking 
the Right Questions:  Advancing an HIV Research Agenda 
for Women and Children.  The recommendations in the 
consensus statement were endorsed by a wide range of 
global stakeholders working on paediatric research issues, 
including research funding agencies, civil society, advocacy 
organizations, industry and UN agencies.2  Since then, the 
IAS has continued advocating for investments in these 
priority research areas, publishing research studies and 
commentaries through the Journal of the International AIDS 
Society, and hosting symposia, special sessions and satellites 
to help promote investment and implementation of the 
consensus statement recommendations. 
Through an unrestricted grant from ViiV Healthcare’s 
Paediatric Innovation Seed Fund, the IAS will expand 
its contribution to the paediatric HIV research field 
by launching the Collaborative Initiative for Paediatric 
HIV Education and Research (CIPHER).  CIPHER is a 
new flagship initiative of the IAS’ Research Promotion 
Department. It is guided by a Scientific and Technical 
Advisory Committee (STAC) composed of clinicians, 
scientists and technical experts from around the world. 
CIPHER addresses two objectives: to invest in and promote 
priority paediatric research; and to strengthen paediatric 
cohort collaboration. 
* PMTCT Prong three is HIV testing and counselling for all pregnant women and access to ARV prophylaxis for HIV-positive pregnant women before, during and after 
delivery; Prong four is better integration of HIV care, treatment and support for women found to be HIV positive and their families.CIPHER Needs Assessment Report http://www.ias-cipher.org
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Objectives of this report
To ensure that CIPHER complements, rather than 
duplicates, opportunities for paediatric researchers 
available through other initiatives, research funding agencies 
or foundations, the first phase of the initiative was a 
comprehensive environmental scan and needs assessment, 
based on key informant interviews with technical experts 
on the STAC and an examination of peer-reviewed 
scientific literature published within the past two years.  
The current report, Evidence for Action:  A Needs 
Assessment of Paediatric HIV Research Priorities, will inform 
CIPHER objectives and refine core activities within each 
objective. It is also intended that the needs assessment 
will support advocacy and collaboration among key 
stakeholders, including activities undertaken to strengthen 
paediatric cohort collaboration.
Methodology
The consensus statement,  Asking the Right Questions: 
Advancing an HIV Research Agenda for Women and Children, 
released in January 2010, was based on a rigorous 
examination of peer-reviewed clinical and operational 
research literature and consultation with scientific, clinical 
and community experts (including a multi-stakeholder 
consultation in Cape Town, South Africa, in 2009).2 
Mapping HIV Research Priorities for Women and Children is 
an environmental scan that documents the results of the 
literature review and consultation.2,3 
The current report builds on that evidence base and 
therefore includes only peer-reviewed scientific literature 
and abstracts published after the consensus statement 
was released. Evidence for Action includes abstracts 
from the 2nd, 3rd and 4th International Workshop on 
HIV Pediatrics, abstracts from the XVIII International 
AIDS Conference (AIDS 2010), abstracts from the 5th 
IAS Conference on HIV Pathogenesis, Treatment and 
Prevention (IAS 2011), oral abstract presentations from 
the XIX International AIDS Conference (AIDS 2012) and 
relevant peer-reviewed scientific literature published from 
January 2010 to August 2012. Structured interviews were 
conducted with six technical experts from the CIPHER 
STAC. 
The following pages reflect the key themes that emerged 
from key informant interviews, peer-reviewed literature 
and conference abstracts, and input from the CIPHER 
STAC. The literature review and key informant interviews 
suggest that the research priorities outlined in the 2010 
consensus statement remain 
relevant to the paediatric 
research field. Key informants 
most frequently identified the 
following clinical and operational 
research areas, which were 
also prominent themes in the 
scientific literature.
...Background
Two of the key 
publications that 
informed this report. 
Above: Mapping HIV 
Research Priorities for 
Women and Children. 
Below: Asking the Right 
Questions: Advancing an 
HIV Research Agenda for 
Women and Children.CIPHER Needs Assessment Report  http://www.ias-cipher.org
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Latest Knowledge & Research Gaps
Clinical Research
Pharmacokinetic and Pharmacodynamic Studies
Clinical experts and available studies suggest that 
pharmacokinetic (PK) and pharmacodynamic (PD) studies 
of interactions between ARVs and drugs to treat co-
morbidities, particularly tuberculosis, malaria and hepatitis, 
are critical for informing optimal clinical management 
of HIV-infected children.4 Several recent studies have 
indicated the impact of such drugs as rifampicin on 
reducing therapeutic ARV drug levels, particularly with 
lopinavir (LPV).5 Studies suggest that only when “super-
boosting” LPV with increased doses of ritonavir is it able 
to reach clinically effective drug concentrations when 
co-administered with rifampicin, and such approaches may 
have significant hepatic toxicities and adherence challenges.6, 
7, 8 
PK and PD data on rifampicin and non-nucleoside reverse 
transcriptase inhibitors are more limited and variable, with 
some studies suggesting that rifampicin reduces drug levels 
of nevirapine, but not other ARVs in this class.9,10 A small 
PK study among Thai children found that co-administration 
of rifampicin and a fixed-dose combination (FDC) of 
nevirapine (NVP), zidovudine (ZDV) and lamivudine at the 
higher end of the NVP dose range (200mg) resulted in 
therapeutically appropriate NVP exposure.11 Given the high 
prevalence of TB and emergence of multi-drug resistant TB 
in sub-Saharan Africa and Asia, more PK and PD studies of 
ARVs co-administered with first- and second-line TB drugs 
are needed to inform clinical management of HIV/TB-co-
infected children. 
Approximately 85% of the 655,000 deaths due to malaria 
in 2010 were among children under five years of age, 
primarily in Africa.12 The interaction of ARVs and malaria 
drugs among infants and children represents an important 
and understudied area of inquiry. Particularly given the 
backdrop of a developing immune system, evidence 
indicates that children co-infected 
with HIV and malaria are more 
likely to develop co-morbidities, 
such as anaemia or cerebral 
malaria.4 Investigation of potential 
drug interactions between 
malaria drugs (particularly the five 
artemesinin-based therapies that 
the World Health Organization 
recommends for use as anti-
malaria combination therapy) and 
paediatric ARVs are required to 
determine optimal timing and 
dosage in paediatric populations in 
malaria-endemic regions. 
PK and PD studies are also 
required to inform optimal 
ARV formulations and dosage 
in the context of nutritional 
supplementation and rehabilitation 
interventions for malnourished 
infants and children.4 PK and 
PD studies of paediatric ARV 
formulations and optimal 
therapeutic dosage with nutritional interventions 
would make important contributions to optimal clinical 
management. 
HIV- and ARV-exposed uninfected infants are also subject 
to certain challenges. Studies have indicated that premature 
delivery and, in some studies, low birth weight are also a 
challenge for ARV- and HIV-exposed uninfected (HEU) 
children, particularly among those exposed to protease 
inhibitor-containing maternal regimens.13 
Finally, presentations at the 4th International Workshop 
on HIV Pediatrics suggested that PK studies may also be 
important in providing information on adherence levels 
Photo from UNAIDS / T. ZnidarcicCIPHER Needs Assessment Report http://www.ias-cipher.org
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given significant self-reporting bias in evaluating adherence, 
particularly among adolescents and older children.14 
Optimal ART Initiation and Management
Updated 2010 World Health Organization (WHO) 
guidelines recommend ART initiation for all children two 
years of age and younger with an HIV diagnosis (based on 
virological testing if under 18 months, serological testing if 
over 18 months or presumptive clinical diagnosis). Available 
data suggest that the earlier ART is initiated (before 
significant attrition of CD4+ T cells occurs), the more 
effective it will be in reducing morbidity and mortality, 
accelerating neurocognitive and physical development and 
enabling CD4+ T cell recovery.15  However, recent studies 
(including data from the PREDICT and PENTA 11 trials) 
suggest that the physical development (based on height-for-
age and weight-for-age) and neurocognitive development 
of HIV-positive children lags behind their HIV-uninfected 
peers even when on ART.16-19 
The PENTA 11/TICCH randomized controlled trial, which 
compared CD4+ T cell-guided treatment interruptions 
with continuous ART, found similar virological and 
immunological outcomes one and two years after the 
end of the trial.20 Discussion and debate regarding this 
potentially controversial strategy at the 4th International 
Workshop on HIV Pediatrics was informed by data 
from the SPARTAC, CHER, PENTA 11/TICCH trials 
presented at the 2012 Conference on Retroviruses and 
Opportunistic Infections (CROI). It underscored the need 
for more definitive, longer-term studies in resource-
limited settings to assess the relative risks and benefits of 
treatment interruption strategies in childhood and their 
impact on (among other measures) bone density, lipids, 
and metabolic, cardiovascular, hepatic and renal functions, 
as well as physical and cognitive development and the 
development of resistance.21-23 
Optimal Paediatric ARV Formulations (First-line, 
Second-line and Salvage Therapy)
Clinicians remain challenged by the limited availability of 
optimal ARV paediatric formulations for first-line, second-
line and salvage therapy.  A cross-sectional analysis of the 
TREAT Asia and International Epidemiologic Databases 
to Evaluate AIDS (IeDEA) southern Africa regional 
cohorts indicated wide variability in access to paediatric 
formulations and in the regimens used (paediatric ART 
regimens were often not consistent with WHO normative 
guidelines).24 
Recent results from the IMPAACT P1060 randomized 
controlled trial, which demonstrated the superiority of 
LPV/r-containing ART regimens compared with NVP-based 
regimens for HIV-infected infants regardless of exposure 
to sdNVP,  may support updating normative guidelines. This 
will have implications for cost and accessibility of optimal 
paediatric ARVs in resource-limited settings.25,26 The 
palatability (especially of LPV/r syrup) and limited availability 
of optimal paediatric ARVs remain significant challenges 
to closing the treatment access gap between adults and 
children. Evaluation of paediatric FDC formulations of 
drugs licensed for adults are required to establish a strong 
evidence base for updated normative guidelines for infants 
and children,27 particularly given the possibility of drug 
resistance when maternal ART is unsuccessful in preventing 
vertical transmission. Additional studies of paediatric ARV 
formulations that take into account exposure to a growing 
range of maternal ART regimens are required to inform 
clinical practice and guidelines. 
WHO released updated technical advice in June 2012, 
lowering the age of tenofovir (TDF)-containing paediatric 
regimens to children two years of age and older. TDF is 
associated with decreased bone mineral density in studies 
of both children and adults. Data in younger children in 
low- and middle-income countries (LMICs) is very limited.28 
Longer-term studies are needed to more definitively 
identify the impact of TDF-containing regimens on bone 
health and other biometric measures, especially in LMICs 
and in younger children where there is little data.
Evaluation of second-generation drugs, such as etravirine, 
and paediatric formulations from new drug classes, such 
as entry inhibitors and integrase inhibitors, will also be 
important for developing more options in the clinical 
management of infants and children.29,30 Studies evaluating 
a range of drug delivery mechanisms of ARVs for infants 
and children, including sprinkles, powders, chewable tablets, 
nanotechnology and microparticles (such as the recent 
IMPAACT P1066 study of a raltegravir sprinkles and the 
CHAPAS 2 study of LPV/r sprinkles formulations), suggest 
that these innovations could provide important new 
treatment options for HIV-infected children that address 
long-standing palatability and adherence challenges of 
existing liquid and tablet formulations.31-33 
...Clinical ResearchCIPHER Needs Assessment Report  http://www.ias-cipher.org
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Short-term and Long-term Impact of in utero ART 
Exposure on HIV-infected Infants, Children and 
Adolescents
WHO issued a programmatic update in April 2012 on 
ART for pregnant women and PMTCT to include “Option 
B+”.34 The programmatic update was driven by both the 
Global Plan Towards the Elimination of New HIV Infections 
Among Children by 2015 and Keeping their Mothers Alive 
(2011-2015) and additional evidence of the efficacy of ART 
in reducing the incidence of TB and other co-morbidities 
(even among individuals with high CD4+ counts). 
Option B+ recommends lifelong triple-drug ART for 
all pregnant women regardless of CD4+ count. Many 
countries are now implementing Option B+ to help meet 
targets to end vertical transmission by 2015. Malawi’s 
early implementation of Option B+ (in July 2011), with 
integrated clinical guidelines for PMTCT, ART and TB, 
resulted in significant uptake of maternal ART, both 
pre- and post-partum.35 However, several clinical experts 
expressed concern that the impact of Option B or B+ 
on paediatric treatment outcomes is unclear, particularly 
given the expanded number of triple-drug options 
recommended for maternal ART, which now include 
TDF/emtracitibine- and efavirenz (EFV)-based regimens in 
addition to existing ZDV- and NVP-based regimens. 
Questions also remain, for example, about the teratogenic 
effects of EFV when used during embryogenesis in the first 
trimester of pregnancy. A recent study indicates a higher 
rate of congenital anomalies in infants exposed to EFV in 
the first trimester compared with other ARVs, although a 
2011 meta-analysis of 21 studies assessing teratogenicity 
among EFV-based (1,290 live births) and non-efavirenz-
based regimens (8,122 live births) found no increased risk 
(RR 0.85).36,37 
Renal dysfunction, changes in bone mineral density and 
reductions in body mass index (BMI) associated with TDF 
exposure has been a clinical concern for paediatric patients, 
with somewhat inconsistent findings on their clinical 
significance.38,39 Data from a cohort of 25 children and 
adolescents, presented at the 4th International Workshop 
on HIV Pediatrics, found elevated levels of parathyroid 
Photo from UNAIDS / Amnon Gutman
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hormone (PTH) among children on TDF-containing ART 
regimens compared with those on TDF-sparing regimens, 
but it was unclear whether this would play a clinically 
relevant role in bone health and development.40 
One of the points raised by several clinical experts is that 
much of the long-term health outcome data are from 
paediatric cohorts in high-income countries, and caution 
should be exercised in extrapolating results to populations 
in low- and middle-income countries given the much higher 
prevalence of malnutrition and other infectious diseases 
endemic in sub-Saharan Africa. A recent randomized 
controlled trial, consistent with earlier observational data, 
demonstrated that PI-containing maternal ART regimens 
result in a higher probability of premature delivery (but 
not increased hospitalization or mortality) compared 
with a triple nucleoside reverse transcriptase inhibitor 
regimen.41 Recent data from a large observational cohort of 
HIV-infected children on ART in Kenya found low height-
for-age and severe immune suppression associated with 
treatment-limiting ART toxicity.42 
Both short-term neonatal outcomes (such as stillbirths, 
underweight and congenital anomalies) and long-term 
health outcome data are needed to assess ART-related 
toxicities and adverse events in resource-limited settings. 
Evidence on other potential long-term effects of ART 
exposure varies; impairment of myocardial growth 
(evaluated by measuring the thickness of the left ventricular 
wall) has been observed,43 as have the metabolic 
dysfunction, reductions in bone mineral density and 
elevated cholesterol levels seen in adult populations.4,44,45 
Worth noting is the need for simplified, standardized 
clinical tools for assessing developmental impairment 
among HIV-positive children on ART. The ASENZE 
study results of the Ten-Questionnaire screening tool, 
which assessed developmental disability in HIV-infected 
and HIV-uninfected children, suggests that simplified 
tools can help identify children at risk of developmental 
delays and impairment early, providing opportunities for 
interventions.46
Short-term and Long-term Impact of in utero ARV 
Exposure on HIV-uninfected Infants and Children
As maternal access to an increasingly diverse range of ART 
regimens expands, evaluating the short-term and long-term 
impact of exposure to maternal ARV in utero and during 
extended breastfeeding in infants and children is becoming 
increasingly critical. 
A 2012 study of early growth parameters of HEU infants 
found no differences in birth weight for gestational age 
between those 
exposed to TDF-
containing maternal 
ART regimens 
versus those without 
tenofovir, but 
slightly lower length-
for-age and head 
circumference-for-age 
measures among TDF-
exposed infants.47 A 
sub-study of the South 
African Development 
of AntiRetroviral 
Therapy (DART) trial 
of HIV-uninfected 
infants exposed 
perinatally to TDF found no increase in congenital, renal 
or growth abnormalities after two years compared with 
(uninfected) population controls, with a similar mortality 
rate at one year of 5%.48 
A PACTG cohort study of HEU children found normal 
motor and mental function scores of ARV-exposed 
children compared with ARV-unexposed children; 
a Botswana study found that lower birth weights in 
ART- and zidovudine-exposed uninfected infants were 
rapidly corrected during the first six months of life.49,50 
Other studies have indicated that ARV exposure in utero 
results in a higher prevalence of mitochondrial toxicity, 
haematological abnormalities and premature delivery 
(particularly in triple-drug maternal regimens).13 
To date, studies of neurodevelopment of HEU infants 
with in utero exposure to ARVs have been reassuring, 
although data, in particular from resource-limited settings, 
is insufficient. Data presented at the 4th International 
Workshop on HIV Pediatrics suggested that although 
HEU children have delays in neurocognitive development 
compared with uninfected controls, the delays remain 
within standard deviations, with no differences in language 
and motor skills.51 Longitudinal studies of HEU populations 
in resource-limited setting are required to more definitively 
assess long-term health and development outcomes of 
ARV-exposed uninfected children. 
...Clinical ResearchCIPHER Needs Assessment Report  http://www.ias-cipher.org
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Optimal Approaches to Screening and Treating Co-
morbidities and Malnutrition
HIV-infected infants and children are at highest risk of 
mortality if they present later in disease progression with 
co-morbidities, such as microbial infections, oral candidiasis, 
TB and/or malnutrition.52 Screening and treatment for 
active TB before ART initiation can reduce the incidence 
of active TB, but can be particularly challenging in paediatric 
populations.53 Studies are required to determine optimal 
TB screening practices, isoniazid preventive therapy (IPT) 
and treatment for active TB among HIV-infected children.
Clinicians debated the relative merits, timing and conflicting 
scientific evidence of IPT pre-exposure prophylaxis for 
HIV-positive children at the 4th International Workshop 
on HIV Pediatrics; several recent studies have provided 
conflicting evidence of the best strategy for IPT 
administration in HIV-positive paediatric populations.54-56 
One consideration is the potential for resistance if IPT 
were broadly implemented. 
Cryptococcal meningitis is a particularly challenging 
opportunistic infection (OI) for people living with HIV; 
recent estimates of the global burden of cryptococcal 
disease among people living with HIV (2007 data) revealed 
an incidence that is highest in sub-Saharan Africa at 3.2% 
(720,000 cases, 70% of which are fatal).57 WHO recently 
released rapid advice on the prevention, diagnosis and 
treatment of cryptococcal disease among HIV-infected 
adults, adolescents and children.58 Clinical experts noted 
the need for studies evaluating optimal approaches to 
screening and treatment of other OIs in paediatric 
populations (including optimal timing and co-administration 
of OI treatment with paediatric ARVs) to inform normative 
guidelines and clinical management.   
Severe acute malnutrition is a major challenge for HIV-
infected children in sub-Saharan Africa, resulting in a wide 
range of metabolic complications, such as electrolyte 
disorders, micronutrient deficiencies and infections.59 A 
recent study of children initiating ART in a Kenyan clinic 
found that food and multivitamin supplementation was 
associated with increased monthly weight gains and height 
gains compared with population controls (younger age at 
ART initiation also strongly correlated with accelerated 
physical development).60
Observational data indicating a strong correlation between 
mortality and undernutrition among HIV-infected children 
on ART (particularly children under two years of age) in a 
Tanzanian cohort (including underweight, wasting and low 
weight-for-age indicators) underscore the need to evaluate 
optimal nutritional supplementation interventions.61 
Evaluating the most effective approaches to nutritional 
rehabilitation and supplementation is urgently required 
given the prevalence of malnutrition (and the attendant 
metabolic impairments) among HIV-infected infants and 
children in low- and middle-income countries. One of the 
challenges in determining the aetiology of underweight 
status among HIV-infected infants is the complex number 
of potential contributors, including TB and other OIs, as 
well as toxicities from ARVs and drugs to treat co-morbid 
conditions.  CIPHER Needs Assessment Report http://www.ias-cipher.org
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Interviewees noted that operational research studies are 
needed to address key programmatic issues for infants, 
children and adolescent populations. Several experts noted 
that operational research is an underfunded area that is 
key to identifying optimal settings and interventions for 
diagnosis, pre-ART care, clinical management (including 
adherence support interventions) and retention once 
children are enrolled in ART programmes.
Early Infant Diagnosis
Experts consistently identified access to reliable, sensitive 
and less expensive virological diagnostics for early infant 
diagnosis (EID) to be one of 
the most urgent needs for HIV-
exposed infants in low- and 
middle-income countries. Studies 
have demonstrated the impact of 
delayed access to EID on increased 
mortality.62 Evaluation of rapid-
test protocols and less expensive 
virological assays (including dried 
blood spot assays to provide 
diagnostic results and baseline 
viral load) are required for EID 
in health care settings delivering 
maternal, newborn and child health 
services.  Also, the prospect of 
new virological point-of-care assays 
may soon change the diagnostics 
landscape in resource-limited 
settings. 
Results from the SAMBA trial, 
designed to evaluate a “test-
and-treat” approach with the 
prototype SAMBA (Simple 
AMplification Based Assay) as 
point-of-care EID, delivered results with the reliability and 
sensitivity of traditional PCR assays.63 Innovative approaches 
to improving earlier diagnosis have included offering it 
as part of childhood immunization clinics’ activities.64 A 
recent prospective study found that using a combination of 
physical indicators (including lymphadenopathy, oral thrush, 
dermatitis and weight) identified 86% of HIV-exposed and 
infected infants, and could help provide a presumptive HIV 
diagnosis for earlier referral to care.65
Linkage to and Retention in Care
WHO has emphasized the need for integrated, 
decentralized service delivery to expand access to HIV 
diagnosis and treatment interventions and reduce loss to 
follow-up.66 Evaluating interventions and models of care 
aimed at improving linkages and referrals among HIV 
screening, pre-ART care and ART programme enrolment 
for children within PMTCT programmes and other health 
care settings was identified by several interviewees as 
key to improving paediatric health outcomes. A recent 
systematic review of PMTCT programmes in India, for 
example, found significant attrition at each stage of the 
cascade, particularly before pregnant women received 
ART.67 Loss to follow-up varies widely across regions; a 
recent multi-regional analysis identified contributing factors 
as recent ART initiation, increased cohort size, fee for 
services and overburdened health facilities.68 
Malawi’s experience in moving to an “Option B+” approach 
in July 2011 included accelerating the decentralization of 
health care to the lowest level of the health care system 
and integrating clinical guidelines on HIV services (including 
PMTCT, pre-ART, ART and early infant diagnosis and 
testing): the number of pregnant or breastfeeding women 
Photo from UNAIDS / C. Giray
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starting ART rose from 18,000 at the end of June to 
34,000 at the end of December.69 The integrated approach 
taken by Malawi also incorporates EID, family planning and 
under-five clinical guidelines. The monitoring and evaluation 
framework, which was implemented in conjunction with 
Malawi’s move to an “Option B+” approach, should 
provide important national data regarding the impact of this 
approach on infant diagnoses and ART access for infants. 
Evaluating the most cost-effective models of integrated 
care (e.g., ART management with immunization, family 
planning and school-based health programmes) are key to 
improving retention in the cascade of care.
Adolescent Adherence and Transition from 
Paediatric to Adult ART Programmes
A key question raised by several experts regarding 
research priorities is how best to manage the rapidly 
growing number of HIV-positive adolescents in ART 
programmes, including evaluating optimal approaches to 
delivering sexual and reproductive health services and 
age-appropriate adherence support. Studies have indicated 
that both adherence and virological response (including 
shorter time to viral rebound among those who achieve 
viral suppression) is poorer in adolescent populations than 
in adult or pre-adolescent populations.70,71 Little data are 
available on evaluating interventions and models of care 
that are most effective in supporting adherence among 
adolescents, and in transitioning adolescents from paediatric 
to adult ART programmes.
Disclosure, Psychosocial Support and HIV/STI 
Prevention
Evaluations of psychosocial and HIV prevention 
interventions for adolescents were identified as important 
research areas, particularly among street-involved and/or 
at-risk youth. Recent data from a US cohort of perinatally 
HIV-infected youth indicated that more than half of those 
who were sexually active were having unprotected sex.72 A 
multi-centre study of five paediatric clinics in Mali, Senegal 
and Côte d’Ivoire found that two-thirds of the 650 children 
over 10 years of age on ART were unaware of their HIV 
status.73 Follow-up data at 36 months indicated a strong 
correlation between HIV disclosure and retention in care 
(93.1% of those who were aware of their HIV status were 
retained in care versus 62.2% of those who were unaware 
of their HIV status). 
A large, multinational cross-sectional study (Malawi, 
Mozambique, Zimbabwe and Zambia) found that some 
of the key challenges facing adolescents living with HIV 
were disclosure, accessing information on sexual and 
reproductive health (including family planning), and 
supportive family and health care environments.74 Data 
from the Baylor Pediatric AIDS Initiative in Botswana found 
that two-thirds of school-age children missed school at least 
once in the preceding month due to HIV and 31% indicated 
that their illness affected their school performance.75 
Identifying effective, family-based approaches for 
parents to inform their HIV-positive children about their 
serostatus and interventions to support HIV and sexually 
transmitted infection (STI) prevention and family planning 
services among adolescents prior to sexual debut are also 
important issues for which there is limited evidence in the 
scientific literature. Recent studies in both high-income and 
resource-limited settings found a high rate of unplanned 
pregnancies (more than 80% of an HIV-positive adolescent 
cohort in the UK and Ireland reported one or more 
unplanned pregnancies) and relatively low rates of condom 
usage as a result of multiple contributing factors, including 
self-agency in negotiating safer sex, peer pressure regarding 
sexual activities and pregnancy, drug or alcohol use, and 
transactional and trans-generational sex.76-78 
Studies have also underscored the disproportionate impact 
of HIV risk among adolescent sub-populations, such as 
young girls who, as a result of both social and biological 
factors, are more vulnerable to HIV infection. Similarly, 
gay, lesbian and bisexual youth face unique challenges, as 
demonstrated by a recent South African study. Discussion 
at the 4th International Workshop on HIV Pediatrics 
highlighted the need to establish long-term studies on 
the efficacy and sustainability of behavioural interventions 
targeting this population. Clinical experts also noted that 
how best to deliver emerging ARV-based biomedical 
prevention interventions (such as Truvada™, which in 
July 2012 was the first-ever drug licensed to prevent HIV 
infection), as well as studies of ARV-based gels and vaginal 
ring microbicides, will become increasingly important with 
a growing number of serodiscordant adolescent couples, 
although clinical data evaluating such interventions among 
adolescent populations are currently lacking.   
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Key informants stressed that CIPHER represents an 
opportunity to conduct retrospective and prospective 
studies and analyses of data from existing paediatric cohorts 
(including opportunities to pool and analyze data across 
cohorts) in both high-income and low- and middle-income 
countries to answer some of these questions. Interviewees 
strongly supported the idea of CIPHER as a “knowledge 
broker” that is able to bring together experts to analyze 
data from disparate cohorts.  
The following clinical and operational priority research 
focus areas were identified through the study of peer-
reviewed scientific literature, which were mentioned in 
the previous sections; they were verified in key informant 
interviews with technical experts and in consultation with 
the STAC. These priorities represent research questions 
that are urgently required to develop optimal interventions 
and approaches to HIV clinical management and service 
delivery, and underscore the unique needs of paediatric 
populations. 
Clinical Research Priorities
•	 Pharmacokinetic and pharmacodynamic studies of 
paediatric antiretrovirals and drugs for co-morbid 
conditions (particularly for TB, malaria, other common 
childhood illnesses and nutritional interventions for 
malnutrition).
•	 Studies evaluating optimal antiretroviral therapy 
initiation, long-term management and complications in 
children (especially children over two years of age) and 
adolescents.
•	 Studies evaluating the short-term and long-term 
impact of in utero exposure to maternal antiretroviral 
therapy and the short-term and long-term impact 
of paediatric antiretroviral therapy on physical and 
cognitive development of HIV-infected infants, children 
and adolescents (key areas include neonatal outcomes, 
metabolism, bone mineral density, and other clinically-
relevant laboratory and biological markers).
•	 Studies evaluating the short-term and long-term impact 
of in utero exposure to maternal antiretroviral therapy 
on physical and cognitive development of HIV-exposed 
uninfected children and adolescents.
•	 Studies evaluating and/or validating diagnostic assays to 
assess neurocognitive and physical development among 
HIV-infected and HIV-exposed uninfected infants and 
children in resource-limited settings.
•	 Evaluations of the most effective interventions to treat 
HIV co-infections and co-morbidities among children 
including TB, malaria, other common opportunistic 
infections and malnutrition.
Operational Research Priorities
•	 Evaluations of interventions to improve access to 
reliable early infant diagnostics, including rapid test 
protocols.
•	 Evaluations and/or validation of simplified, standardized 
diagnostic tools to assess neurocognitive and physical 
development in HIV-exposed infected or uninfected 
infants, children 
and adolescents in 
resource-limited 
settings.
•	 Studies evaluating 
interventions and 
optimal models 
for integrating 
paediatric HIV 
services with 
maternal, newborn 
and child health 
and other health 
services.
•	 Studies evaluating interventions and optimal models for 
promoting early post-natal and long-term programme 
retention and reducing loss to follow-up.
•	 Studies evaluating optimal approaches to support 
childhood and adolescent adherence and transition to 
adult antiretroviral therapy programmes.
•	 Studies evaluating the most effective interventions to 
support disclosure, access to psychosocial and sexual 
and reproductive health services, delivery of biomedical 
HIV and STI prevention interventions for adolescents. 
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The research priorities outlined in the 2010 consensus 
statement,  Asking the Right Questions:  Advancing an HIV 
Research Agenda for  Women and Children, remain relevant 
to the paediatric research field. A major barrier to 
developing optimal interventions and approaches to HIV 
clinical management and service delivery for paediatric 
populations is that in many areas there is either limited or 
no data on infants, children and adolescents, especially in 
low- and middle-income countries. The role of CIPHER 
as a forum for strengthening cohort collaboration is 
supported by key informants. The main areas of clinical and 
operational research and the identified research priorities 
outlined in this document will serve as a basis for guiding 
future CIPHER activities. 
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